YZYushi Zhang

Yushi Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yushi Zhang has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Han-Zhong Li

    Peking Union Medical College Hospital

    10 shared publications
  • Hanzhong Li

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China

    8 shared publications
  • Yi Cai

    Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, P.R. China

    7 shared publications
  • Mingxin Zhang

    Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, China

    6 shared publications
  • Haidan Sun

    Proteomics Research Center, Core Facility of Instrument, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    5 shared publications
  • Wei Sun

    Proteomics Research Center, Core Facility of Instrument, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, China

    5 shared publications

Latest Publications

  • Urinary proteome and metabolome uncover tumor microenvironment and cellular metabolism changes of renal clear cell carcinoma

    by Xiaoyan Liu, Mingxin Zhang, Yi Zhao, Yuting Dai, Chongxu Han, Jing Chen, Haidan Sun, Zhengguang Guo, Feng Qi, Yuxue Zhang, et al.

    Background Clear cell renal carcinoma (ccRCC) is the most frequent form of kidney tumors with high recurrence and progression rates. Early diagnosis of ccRCC could significantly improve survival rate. Liquid biopsies could capture molecular information which would not only shed more light on the signatures of the onset of ccRCC, but also discover potential biomarker for early diagnosis. Method We applied LC-MS to profile the urine proteome and metabolome of 314 ccRCC, 341 healthy control and 49 kidney benign disease enrolled from three cohorts. Further cell origin annotation and protein-protein correlation analysis were performed to explain the possible TME mechanistic. Results We revealed significant changes of extracellular matrix (ECM) organization, complement and coagulation cascades, amino acid metabolism and fatty acid metabolism in ccRCC. Cell origin annotation of cancer proteins revealed the potential role of myofibroblast cell during ECM organization. Finally, we discovered six potential urinary biomarkers, FGB,CILP, ITIH1, GUCA2B, anserine, oxindole and established models for ccRCC diagnosis with the AUC value of 0.84, 0.80 and 0.86 for protein model, metabolites model and multi-omics model in an external cohort. The protein model also showed discriminatory ability for ccRCC and benign with the AUC value of 0.75. Conclusion Present study provided urinary molecular changes, which could reflect TME disorder and cellular metabolism reprogramming.

  • Retraction
    Open Access

    [Retracted] Downregulation of microRNA-206 suppresses clear cell renal carcinoma proliferation and invasion by targeting vascular endothelial growth factor A

    by Yi Cai, Hanzhong Li, Yushi Zhang

    Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that there appeared to be several instances of overlapping data panels comparing between the Transwell invasion and migration assay images shown in Figs. 2E and 4G, such that data which were intended to show the results from differently performed experiments were apparently derived from a (much) smaller number of original sources. Given the number of cases of overlapping data panels both within and between this pair of figures in the article itself, the Editor of Oncology Reports has decided that this paper should be retracted from the Journal on the basis of a lack of confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a reply. The Editor apologizes to the readership for any inconvenience caused. [Oncology Reports 35: 1778-1786, 2016; DOI: 10.3892/or.2015.4538].

  • Open Access

    Blood- and Urine-Based Liquid Biopsy for Early-Stage Cancer Investigation: Taken Clear Renal Cell Carcinoma as a Model

    by Xiaoyan Liu, Mingxin Zhang, Chen Shao, Haidan Sun, Binbin Zhang, Zhengguang Guo, Jiameng Sun, Feng Qi, Yushi Zhang, Haitao Niu, et al.


  • Open Access

    Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China

    by Cong Luo, Ye Zhang, Yu-Shi Zhang, Ming-Xin Zhang, Jun Ning, Min-Feng Chen, Yuan Li, Lin Qi, Xiong-Bing Zu, Yang-Le Li, et al.

    Purpose: To explore the relationship between the genotype and renal phenotype in a Chinese cohort and guide clinical decision-making for treating tuberous sclerosis complex (TSC).Materials and methods: We reviewed 173 patients with definite TSC at three centers in China from September 2014 to September 2020. All the patients underwentTSC1andTSC2genetic testing as well as renal phenotypic evaluation. All analyses were performed using the SPSS software, version 19.0, with a cut-offPvalue of 0.05 considered statistically significant.Results: We identified variants in 93% (161/173) cases, including 16%TSC1and 77%TSC2variants. Analysis of the relationship between the genotype and renal phenotype, revealed that those withTSC2variants were more likely to develop severe renal AML (> 4) (P = 0.044). In terms of treatment,TSC2variants were more likely to undergo nephrectomy/partial nephrectomy (P = 0.036) and receive mTOR medication such as everolimus (P < 0.001). However, there was no significant difference between the two groups in terms of their response to the everolimus treatment.Conclusion: Patients withTSC2variants exhibit more severe renal phenotypes, especially those associated with renal angiomyolipomas (AML), and they often require nephrectomy/partial nephrectomy or mTOR medication. Detection of the genotype is helpful in TSC management.


  • Open Access

    Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker

    by Xiaoyan Liu, Mingxin Zhang, Xiang Liu, Haidan Sun, Zhengguang Guo, Xiaoyue Tang, Zhan Wang, Jing Li, Lu He, Wenli Zhang, et al.

    Plasma metabolomics and lipidomics have been commonly used for biomarker discovery. Studies in white and Japanese populations suggested that gender and age can affect circulating plasma metabolite profiles; however, the metabolomics characteristics in Chinese population has not been surveyed. In our study, we applied liquid chromatography-mass spectrometry-based approach to analyze Chinese plasma metabolome and lipidome in a cohort of 534 healthy adults (aging from 15 to 79). Fatty-acid metabolism was found to be gender- and age-dependent in Chinese, similar with metabolomics characteristics in Japanese and white populations. Differently, lipids, such as TGs and DGs, were found to be gender-independent in Chinese population. Moreover, nicotinate and nicotinamide metabolism was found to be specifically age-related in Chinese. The application of plasma metabolome and lipidome for renal cell carcinoma diagnosis (143 RCC patients and 34 benign kidney tumor patients) showed good accuracy, with an area under the curve (AUC) of 0.971 for distinction from healthy control, and 0.839 for distinction from the benign. Bile acid metabolism was found to be related to RCC probably combination with intestinal microflora. Definition of the variation and characteristics of Chinese normal plasma metabolome and lipidome might provide a basis for disease biomarker analysis.


  • Open Access

    LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma

    by Xiang Liu, Mingxin Zhang, Xiangming Cheng, Xiaoyan Liu, Haidan Sun, Zhengguang Guo, Jing Li, Xiaoyue Tang, Zhan Wang, Wei Sun, et al.

    Bladder cancer (BC) and Renal cell carcinoma(RCC) are the two most frequent genitourinary cancers in China. In this study, a comprehensive liquid chromatography—mass spectrometry (LC-MS) based method, which utilizes both plasma metabolomics and lipidomics platform, has been carried out to discriminate the global plasma profiles of 64 patients with BC, 74 patients with RCC, and 141 healthy controls. Apparent separation was observed between cancer (BC and RCC) plasma samples and controls. The area under the receiving operator characteristic curve (AUC) was 0.985 and 0.993 by plasma metabolomics and lipidomics, respectively (external validation group: AUC was 0.944 and 0.976, respectively). Combined plasma metabolomics and lipidomics showed good predictive ability with an AUC of 1 (external validation group: AUC = 0.99). Then, separation was observed between the BC and RCC samples. The AUC was 0.862, 0.853 and 0.939, respectively, by plasma metabolomics, lipidomics and combined metabolomics and lipidomics (external validation group: AUC was 0.802, 0.898, and 0.942, respectively). Furthermore, we also found eight metabolites that showed good predictive ability for BC, RCC and control discrimination. This study indicated that plasma metabolomics and lipidomics may be effective for BC, RCC and control discrimination, and combined plasma metabolomics and lipidomics showed better predictive performance. This study would provide a reference for BC and RCC biomarker discovery, not only for early detection and screening, but also for differential diagnosis.


  • Open Access

    Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC

    by Xiaoyan Liu, Mingxin Zhang, Xiang Liu, Haidan Sun, Zhengguang Guo, Xiaoyue Tang, Zhan Wang, Jing Li, Hanzhong Li, Wei Sun, et al.

    Renal cell carcinoma (RCC) is the second most lethal urinary cancer. RCC is frequently asymptomatic and it is already metastatic at diagnosis. There is an urgent necessity for RCC specific biomarkers selection for diagnostic and prognostic purposes. In present study, we applied liquid chromatography—mass spectrometry (LC-MS) based metabolomics to analyze urine samples of 100 RCC, 34 benign kidney tumors and 129 healthy controls. Differential metabolites were analyzed to investigate if urine metabolites could differentiate RCC from non-RCC. A panel consisting of 9 metabolites showed the best predictive ability for RCC from the health controls with an area under the curve (AUC) values of 0.905 for the training dataset and 0.885 for the validation dataset. Separation was observed between the RCC and benign samples with an AUC of 0.816. RCC clinical stages (T1 and T2 vs. T3 and T4) could be separated using a panel of urine metabolites with an AUC of 0.813. One metabolite, N-formylkynurenine, was discovered to have potential value for RCC diagnosis from non-RCC subjects with an AUC of 0.808. Pathway enrichment analysis indicated that tryptophan metabolism was an important pathway in RCC. Our data concluded that urine metabolomics could be used for RCC diagnosis and would provide candidates for further targeted metabolomics analysis of RCC.


  • Open Access

    Correction: miR-9-5p, miR-124-3p, and miR-132-3p regulate BCL2L11 in tuberous sclerosis complex angiomyolipoma

    by Yi Cai, Wenda Wang, Hao Guo, Hanzhong Li, Yu Xiao, Yushi Zhang


  • Interleukin-6-Producing Pheochromocytoma as a New Reason for Fever of Unknown Origin: A Retrospective Study

    by Xiangming Cheng, Mingxin Zhang, Yu Xiao, Hanzhong Li, Yushi Zhang, Zhigang Ji